Jay Harper
Director, Oncology Targeted Discovery, AstraZeneca
Seminars
Re-join your expert speakers in a closing panel discussion as they debate the impact of ADC combination within oncology treatment landscape, best strategy to smartly select combination partners, and ability to combat ADC patient
resistance. Come with your thoughts and questions prepared!
In an ever-growing clinical landscape and with the threat of patient resistance, the role of combinations is crucial to bring better ADC treatments to oncology patients.
Join this long-standing seminar day for an overview of ADC clinical combination leaders, assess applications of dual payload ADCs to tackle payload resistance, and delve into rationale-driven practices to smartly select and investigate the right ADC combination partners
Download the Full Event Guide for full details
- Optimizing strategy for ADC combination trials
- Overviewing exciting ADC combination data generated in 2025
- Looking to the future: what are the next steps for progressing ADC combinations?
